TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02479308
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration
Study: NCT02479308
Drug: ALKS 5461
Normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration for a total of 12 dosing days
Study: NCT00583427
Drug: Sulodexide
Normalized name: sulodexide
DrugBank: Sulodexide (DB06271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg per day in an oral gelcap form
Study: NCT01392469
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Film coated tablets, oral administration
Study: NCT02269579
Drug: CPX-351
Normalized name: CPX
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01794143
Drug: DPP-4 inhibitor (sitagliptin)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used in accordance with labeling and/or usual practice
Study: NCT01794143
Drug: GLP-1 receptor agonist (liraglutide)
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Used in accordance with labeling and/or usual practice.
Study: NCT01794143
Drug: Insulin (glargine)
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used in accordance with labeling and/or usual practice.
Study: NCT01392469
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Administration
Study: NCT01124864
Drug: AUY922
Normalized name: AUY922
DrugBank: AUY922 (DB11881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.
Study: NCT01243242
Drug: Metadoxine (MG01CI)
Normalized name: metadoxine
DrugBank: Metadoxine (DB16554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG01CI 1400 mg, that will be taken daily by the patients for a duration of 6 weeks.
Study: NCT03263663
Drug: targeted substance according to the avatar model
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: individualized second line treatment
Study: NCT00005642
Drug: semaxanib
Normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a dose-deescalation study. Patients receive SU5416 IV over 1 hour twice weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 6-12 patients receive deescalating doses of SU5416 until the maximum target-inhibiting dose (MTID) is determined.
Study: NCT02682862
Drug: olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily
Study: NCT02682862
Drug: olodaterol 2.5 mcg
Normalized name: olodaterol 2.5 mcg/inh inhalation aerosol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily
Study: NCT01392469
Drug: Bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Administration
Study: NCT03844945
Drug: Netarsudil Ophthalmic Solution 0.01%
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical sterile ophthalmic solution
Study: NCT03844945
Drug: Netarsudil Ophthalmic Solution 0.02%
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical sterile ophthalmic solution
Study: NCT03844945
Drug: Netarsudil Ophthalmic Solution 0.04%
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical sterile ophthalmic solution
Study: NCT01264653
Drug: adrenalin
Normalized name: Adrenalin
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adrenalin 0.01%
Study: NCT00049556
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01277770
Drug: Evaluation of the DGF nomogram in Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An evaluation of the DGF nomogram in Thymoglobulin treated recipients at the University of Minnesota
Study: NCT00082862
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00082862
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00283335
Drug: gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03945604
Drug: SHR-1210 + Apatinib +Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.
Study: NCT04455464
Drug: Midodrine Oral Tablet
Normalized name: midodrine Oral Tablet
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midodrine will be given 10 mg for one time only.
Study: NCT02817425
Drug: SOX
Normalized name: Vasoxyl
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. Every 21 days as a cycle
Study: NCT02113137
Drug: group 1: drug: chlorine dioxide
DrugBank: Chlorine (DB11109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 1 - additional use of 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing.
Study: NCT00632606
Drug: magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: magnesium sulfate 2 grams intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
Study: NCT00632606
Drug: metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
Study: NCT01511120
Drug: acetated Ringer's solution
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01326338
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days
Study: NCT02490670
Drug: Cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02230514
Drug: XCEL-MT-OSTEO-ALPHA
Normalized name: Osteo-Poretical
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue in association with open surgery
Study: NCT00492635
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 months DAILY dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
Study: NCT00492635
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 months PRN dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
Study: NCT01812668
Drug: cabozantinib-s-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00552188
Drug: VIA-2291
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
DrugBank: Palopegteriparatide (DB18676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, oral dosing, 1 time daily for 24 weeks
Study: NCT02160899
Drug: ISIS-APO(a)Rx
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
Study: NCT03867370
Drug: Toripalimab (JS001 )
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03867370
Drug: Toripalimab (JS001 ) Lenvatinib
Normalized name: Toripalimab
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV 4 mg capsules
Study: NCT04952155
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment. The adminstration course was 24 weeks.. The 24-week follow-up period was followed after the treatment.
Study: NCT00732407
Drug: aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren will be given in a preliminary dosage of 150 mg per day, after a follow up of two weeks dosage will be increased to 300 mg per day.
Study: NCT00732407
Drug: losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan will be given in a preliminary dosage of 50 mg per day and after a two weeks follow up dosage will be increased to 100 mg per day
Study: NCT00272896
Drug: Vasoactive intestinal peptide
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01168219
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC or IV
Study: NCT01168219
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01168219
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01168219
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or IV
Study: NCT00747734
Drug: MNRP1685A
Normalized name: MNRP1685A
DrugBank: Vesencumab (DB15428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating intravenous dose
Study: NCT00490529
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m² by infusion
Study: NCT00490529
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
Study: NCT00994344
Drug: Darunavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir/ritonavir 800/100 mg once daily
Study: NCT00994344
Drug: Lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir/ritonavir 400/100 mg twice daily
Study: NCT02078960
Drug: Omacetaxine mepesuccinate
Normalized name: Omacetaxine Mepesuccinate
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.5 mg omacetaxine mepesuccinate and 10 mg mannitol; The first dose of the day for cycle 1 will be administered at the investigational center. Subsequent doses (in prefilled syringes) may be administered on an outpatient basis after training takes place
Study: NCT02683603
Drug: AS colistin and imipenem
Normalized name: imipenem and cilastatin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: colimycin (colistin) powder (1 million units (MU) by flakon) by AS route in addition to imipenem
Study: NCT02683603
Drug: IV colistin  and imipenem .
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: colimycin (colistin) powder (1 MU by flakon) by intravenous route in addition to imipenem
Study: NCT02683603
Drug: AS colimycin (colistin)
Normalized name: Colimycin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nebulisation of colimycin (colistin) for 30 minutes 3 times per day during at least 14 days. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland).
Study: NCT02683603
Drug: IV colimycin (colistin)
Normalized name: Colimycin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous colimycin (colistin) : 9 MU during 60 minutes followed by 4.5 million units 2 times per day
Study: NCT02683603
Drug: AS colistin and imipenem
Normalized name: imipenem and cilastatin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV imipenem 1 g three times per day.
Study: NCT02683603
Drug: IV colistin and imipenem
Normalized name: imipenem and cilastatin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV imipenem 1 g three times per day
Study: NCT02584556
Drug: systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.
Study: NCT02584556
Drug: Transcatheter Arterial Chemoembolization
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.
Study: NCT02870478
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing frequency comparison, using atropine sulfate 1% solution diluted to 0.01% and 0.05% by Leiter's Compounding Pharmacy
Study: NCT02468167
Drug: N-butyl-2-cyanoacrylate
Normalized name: N-butyl-2-cyanoacrylate
DrugBank: Enbucrilate (DB12358)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04657666
Drug: Nabiximols
Normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oromucosal spray
Study: NCT03961698
Drug: IPI-549 (eganelisib)
Normalized name: Ipilimumab
DrugBank: IPI-549 (DB16296)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IPI-549 is an oral, selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma). It is an orally-administered capsule that will be dosed at either 20mg/day, 30mg/day, or 40mg/day to patients in both cohorts A and B depending on the results of the safety run-in phase for each cohort.
Study: NCT03961698
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). 840 mg of the drug will be administered intravenously (IV) on days 1 and 15 in combination of each 28-day cycle for patients with TNBC. 1200mg will be administered IV on day 1 of each 21-day cycle to patients with RCC.
Study: NCT03300804
Drug: 20-herb formulation
Normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks
Study: NCT01077167
Drug: Omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment.
Study: NCT01790139
Drug: Oral simethicone
Normalized name: simethicone Oral Capsule
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of simethicone is administered as an agent to prevent colonic bubbles
Study: NCT03961698
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel (Taxol), a mitotic inhibitor chemotherapy, with less toxicity than solvent-based (sb) paclitaxel and achieves a 33% higher tumor uptake in preclinical models. Nab-paclitaxel will be administered intravenously (IV) at 100 mg/m2 on days 1, 8 and 15 of each 28-day cycle for patients with TNBC.
Study: NCT03961698
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) recombinant monoclonal antibody that is approved by the FDA for the treatment of multiple solid tumors in combination with chemotherapy. It will be administered at 15 mg/kg IV on day 1 of each 21-day cycle to patients with RCC.
Study: NCT00229424
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of famotidine by 40mg/day along with lafutidine placebo
Study: NCT01224951
Drug: Beclomethasone
Normalized name: Beclomethasone
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microgram of beclomethasone will be given to the patients in arm 1. During the last 4 weeks, the patients will receive additional 400 microgram of Qvar.
Study: NCT00260962
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a 2-week baseline period, olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of at 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of of 10 mg/day.
Study: NCT04270760
Drug: Olpasiran
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 Dose 2 Dose 3 Dose 4
Study: NCT00926029
Drug: Fluoride
Normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush twice daily
Study: NCT00926029
Drug: Triclosan, fluoride
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush twice daily
Study: NCT00718588
Drug: MTRX1011A
DrugBank: TRX1 (DB05863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous and intravenous single and repeating dose
Study: NCT01766258
Drug: ODM-101 65mg Carbidopa
Normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01766258
Drug: ODM-101 105mg Carbidopa
Normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01766258
Drug: Stalevo
Normalized name: Stalevo
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01738646
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01738646
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04303039
Drug: ABP-671
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABP-671 Tablet 1.0 mg
Study: NCT00591318
Drug: ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 grams of ceftriaxone given daily, Monday to Friday, excluding major holidays, for a total of 40 doses
Study: NCT00647270
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pre-filled syringe. See arm for more detail
Study: NCT02523144
Drug: Chloral Hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70mg/kg chloral hydrate
Study: NCT02523144
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mcg/kg
Study: NCT02523144
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3mcg/kg
Study: NCT00233883
Drug: enfuvirtide [Fuzeon]
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90mg sc bid by Biojector 2000 NFID for 4 weeks
Study: NCT00233883
Drug: enfuvirtide [Fuzeon]
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90mg sc bid by 27G1/2 needle/syringe for 4 weeks
Study: NCT02157181
Drug: 2CdA +/- Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m² infusion
Study: NCT01529138
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination treatment with temsirolimus and axitinib
Study: NCT01529138
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combination treatment with temsirolimus and axitinib
Study: NCT00131053
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00131053
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00131053
Drug: Pirarubicin
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no